Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer

被引:14
|
作者
Kim, Tae Hyuk [1 ]
Ki, Chang-Seok [2 ]
Hahn, Soo Yeon [3 ]
Oh, Young Lyun [4 ]
Jang, Hye Won [5 ]
Kim, Sun Wook [1 ]
Chung, Jae Hoon [1 ]
Shin, Jung Hee [3 ]
机构
[1] Sungkyunkwan Univ, Div Endocrinol & Metab, Dept Med, Thyroid Ctr,Sch Med,Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Dept Med Educ, Sch Med, Seoul, South Korea
关键词
TERT promoter; Thyroid cancer; Papillary cancer; Ultrasonography; Prediction; BRAF(V600E) MUTATION; NODULES; ASSOCIATION; CARCINOMA; MANAGEMENT; DIAGNOSIS; MELANOMA; BREAST;
D O I
10.1007/s12020-017-1340-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose Telomerase reverse transcriptase promoter mutations are found in highly aggressive thyroid malignancies. Our aim was to define the ultrasonographic features of telomerase reverse transcriptase promoter-mutated papillary thyroid cancer and to evaluate their predictive performances. Methods Ultrasonographic findings were reviewed for 185 patients with surgically confirmed papillary thyroid cancer between 1994 and 2004. Genomic DNA to identify telomerase reverse transcriptase promoter mutations was extracted from archived surgical specimens. Logistic regression analysis was performed to compare clinical factors and ultrasonographic findings between telomerase reverse transcriptase promoter-mutated and wild-type papillary thyroid cancers. Results A telomerase reverse transcriptase promoter mutation was detected in 8.1% (15 of 185) of specimens from papillary thyroid cancer patients with a strong trend toward increasing age. Nonparallel orientation and microlobulated margin were independent ultrasonographic findings for predicting telomerase reverse transcriptase promoter-mutated papillary thyroid cancer in patients over 50 years (odds ratio 5.898, 95% confidence interval 1.092-31.851, P = 0.039 for orientation; odds ratio 5.813, 95% confidence interval 1.320-25.602, P = 0.020 for margin). Prevalence of telomerase reverse transcriptase promoter mutations increased to 50.0% in papillary thyroid cancer patients older than 50 years with both ultrasonographic findings and was 0% in patients without either finding. For identifying telomerase reverse transcriptase promoter-mutated papillary thyroid cancer, ultrasonographic had 64.3% sensitivity, 80.8% specificity, 50.0% positive predictive value and 88.4% negative predictive value. Conclusions Telomerase reverse transcriptase promoter-mutated papillary thyroid cancer could be suggested by the ultrasonographic features of nonparallel orientation and microlobulated margin in patients older than 50 years. Prebiopsy recognition of this unique ultrasonographic pattern would mandate the nodule fall into a "biopsy suggested" category.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 50 条
  • [21] Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
    Pirker, Christine
    Bilecz, Agnes
    Grusch, Michael
    Mohr, Thomas
    Heidenreich, Barbara
    Laszlo, Viktoria
    Stockhammer, Paul
    Loetsch-Gojo, Daniela
    Gojo, Johannes
    Gabler, Lisa
    Spiegl-Kreinecker, Sabine
    Dome, Balazs
    Steindl, Ariane
    Klikovits, Thomas
    Hoda, Mir Alireza
    Jakopovic, Marko
    Samarzija, Miroslav
    Mohorcic, Katja
    Kern, Izidor
    Kiesel, Barbara
    Brcic, Luka
    Oberndorfer, Felicitas
    Muellauer, Leonhard
    Klepetko, Walter
    Schmidt, Wolfgang M.
    Kumar, Rajiv
    Hegedus, Balazs
    Berger, Walter
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3819 - 3830
  • [22] Telomerase reverse transcriptase promoter alterations in human bladder cancer
    Turan, Sevilay
    CANCER RESEARCH, 2014, 74 (19)
  • [23] TARGETING TELOMERASE VIA MEK INHIBITION IN AGGRESSIVE TERT PROMOTER MUTATED BRAIN TUMORS
    Loetsch-Gojo, Daniela
    Gabler, Lisa
    Jaunecker, Carola
    Fuernweger, Kerstin
    Bruckner, Katharina
    Mayr, Lisa
    Madlener, Sibylle
    Kirchhofer, Dominik
    Spiegl-Kreinecker, Sabine
    Roessler, Karl
    Berger, Walter
    Gojo, Johannes
    NEURO-ONCOLOGY, 2021, 23 : 39 - 40
  • [24] A second family with a telomerase reverse transcriptase (TERT) promoter gene mutation associated with melanomas
    Tang, D. Y. L.
    O'Shea, S.
    Espinoza, D.
    Rajan, N.
    Carmichael, A.
    Newton-Bishop, J. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 : 82 - 82
  • [25] Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma
    Kwa, Wit Thun
    Effendi, Kathryn
    Yamazaki, Ken
    Kubota, Naoto
    Hatano, Mami
    Ueno, Akihisa
    Masugi, Yohei
    Sakamoto, Michiie
    PATHOLOGY INTERNATIONAL, 2020, 70 (09) : 624 - 632
  • [26] Telomerase Reverse Transcriptase (TERT) Gene Variations and Susceptibility of Colorectal Cancer
    Jannuzzi, Ayse Tarbin
    Karaman, Ecem
    Oztas, Ezgi
    Yanar, Hakan Teoman
    Ozhan, Gul
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2015, 19 (12) : 692 - 697
  • [27] Highly prevalent TERT promoter mutations in aggressive thyroid cancers
    Liu, Xiaoli
    Bishop, Justin
    Shan, Yuan
    Pai, Sara
    Liu, Dingxie
    Murugan, Avaniyapuram Kannan
    Sun, Hui
    El-Naggar, Adel K.
    Xing, Mingzhao
    ENDOCRINE-RELATED CANCER, 2013, 20 (04) : 603 - 610
  • [28] Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients
    Capezzone, Marco
    Cantara, Silvia
    Marchisotta, Stefania
    Filetti, Sebastiano
    De Santi, Maria Margherita
    Rossi, Benedetta
    Ronga, Giuseppe
    Durante, Cosimo
    Pacini, Furio
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10): : 3950 - 3957
  • [29] ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer
    Bullock, Martyn
    Lim, Grace
    Zhu, Ying
    Aberg, Helena
    Kurdyukov, Sergey
    Clifton-Bligh, Roderick
    THYROID, 2019, 29 (11) : 1623 - 1633
  • [30] Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.
    El Zarif, Talal
    Machaalani, Marc
    Nawfal, Rashad
    Xie, Wanling
    Choueiri, Toni K.
    Pomerantz, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)